Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May 5;386(18):1770-1771.
doi: 10.1056/NEJMc2202305.

Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply

Affiliations
Comment

Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply

Bob T Li et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Since publication of their article, the authors report no further potential conflict of interest.

Comment on

References

    1. Li BT, Michelini F, Misale S, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov 2020;10:674–87. - PMC - PubMed
    1. Haikala HM, Lopez T, Köhler J, et al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd. Cancer Res 2022;82:130–41. - PMC - PubMed
    1. Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 2020;10:688–701. - PMC - PubMed
    1. Powell CA, Modi S, Iwata H, et al. Abstract CT167: pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. Cancer Res 2021; 81:Suppl 13:CT167. abstract.
    1. Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease — focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022. January 14 (Epub ahead of print). - PubMed

MeSH terms